News Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy Heartseed & Novo Nordisk say a patient has been successfully dosed with cell therapy HS-001.
News Lilly strikes $1.9bn kidney disease alliance with Ascidian In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
